Next-Generation Sequencing Test for Cutaneous Melanoma
Next-Generation Sequencing Test for Cutaneous Melanoma

Sponsor: Castle Biosciences


Castle Biosciences has launched DecisionDx-CMSeq test that uses next-generation sequencing (NGS) to identify somatic mutations in genes relevant to cutaneous melanoma (CM). The test will complement the company’s DecisionDx-Melanoma GEP test that predicts individual risk of recurrence in patients with melanoma. DecisionDx-CMSeq evaluates DNA mutations in the BRAF and NRAS genes and can be ordered in conjunction with the DecisionDx-Melanoma GEP test, or as a standalone. BRAF is found in approximately 40 to 50% of CM tumors. The DecisionDx-CMSeq test analyzes mutations in exon 15 of BRAF, where the most common and clinically actionable mutations occur. And roughly 20% of melanoma tumors exhibit NRAS mutations. The test identifies mutations affecting codons G12, G13, and Q61 of the NRAS gene.

This site uses Akismet to reduce spam. Learn how your comment data is processed.